T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Canadian Natural Resources
CNQ
|
+$759M |
| 3 |
Becton Dickinson
BDX
|
+$735M |
| 4 |
Ashland
ASH
|
+$669M |
| 5 |
Keysight
KEYS
|
+$573M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$1.73B |
| 2 |
Ecolab
ECL
|
+$1.17B |
| 3 |
Crown Castle
CCI
|
+$906M |
| 4 |
Phillips 66
PSX
|
+$775M |
| 5 |
Gilead Sciences
GILD
|
+$756M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.84% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.41% |
| 4 | Industrials | 12.4% |
| 5 | Technology | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NHC.PRA
1201
DELISTED
NATIONAL HEALTHCARE CORP PFD CONV SER A (DE)
NHC.PRA
| $15.2M | ﹤0.01% |
980,639
-7,178
| -0.7% | -$111K |
|
1202
Labcorp
LH
$26.2B
| $15.2M | ﹤0.01% |
163,973
+361
| +0.2% | +$31.9K |
|
1203
MarketAxess Holdings
MKTX
$5.72B
| $15.1M | ﹤0.01% |
210,600
+28,900
| +16% | +$1.9M |
|
1204
Suncor Energy
SU
$76.5B
| $15.1M | ﹤0.01% |
474,955
+435,155
| +1,093% | +$14.4M |
|
|
INFI
1205
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $15.1M | ﹤0.01% |
892,070
-133,150
| -13% | -$1.94M |
|
|
NXEO
1206
DELISTED
Nexeo Solutions, Inc. Common Stock
NXEO
| $15M | ﹤0.01% |
1,463,400
| – | – |
|
|
DNB
1207
DELISTED
Dun & Bradstreet
DNB
| $15M | ﹤0.01% |
123,935
+63,400
| +105% | +$7.66M |
|
|
SCG
1208
DELISTED
Scana
SCG
| $14.9M | ﹤0.01% |
247,389
+1,121
| +0.5% | +$62.1K |
|
1209
Donaldson
DCI
$11.1B
| $14.9M | ﹤0.01% |
386,042
-25,300
| -6% | -$1.01M |
|
|
GRA
1210
DELISTED
W.R. Grace & Co.
GRA
| $14.9M | ﹤0.01% |
156,202
-13,168
| -8% | -$1.23M |
|
1211
Clean Harbors
CLH
$16.9B
| $14.9M | ﹤0.01% |
309,800
-1,070,560
| -78% | -$52.2M |
|
1212
Ironwood Pharmaceuticals
IRWD
$674M
| $14.9M | ﹤0.01% |
1,158,920
-532,621
| -31% | -$6.1M |
|
|
CRRC
1213
DELISTED
COURIER CORP
CRRC
| $14.8M | ﹤0.01% |
994,677
-76,620
| -7% | -$1.06M |
|
|
NWHM
1214
DELISTED
THE NEW HOME COMPANY INC.
NWHM
| $14.8M | ﹤0.01% |
1,023,723
+63,023
| +7% | +$895K |
|
|
CAA
1215
DELISTED
CalAtlantic Group, Inc.
CAA
| $14.7M | ﹤0.01% |
402,650
-188,482
| -32% | -$6.99M |
|
1216
M/I Homes
MHO
$3.9B
| $14.7M | ﹤0.01% |
639,010
-881,550
| -58% | -$19.2M |
|
|
ARC
1217
DELISTED
ARC Document Solutions, Inc.
ARC
| $14.6M | ﹤0.01% |
1,424,742
+14,200
| +1% | +$136K |
|
|
SEE
1218
DELISTED
Sealed Air
SEE
| $14.5M | ﹤0.01% |
342,331
+2,777
| +0.8% | +$104K |
|
|
VIRX
1219
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $14.5M | ﹤0.01% |
27,000
-2,693
| -9% | -$1.21M |
|
|
QUNR
1220
DELISTED
Qunar Cayman Islands Limited
QUNR
| $14.2M | ﹤0.01% |
500,293
-1,771,514
| -78% | -$47.1M |
|
1221
D.R. Horton
DHI
$41.9B
| $14.2M | ﹤0.01% |
561,770
+4,640
| +0.8% | +$109K |
|
|
EBSB
1222
DELISTED
Meridian Bancorp, Inc.
EBSB
| $14.2M | ﹤0.01% |
+1,261,785
| New | +$14M |
|
1223
Allot
ALLT
$388M
| $14.1M | ﹤0.01% |
1,531,880
+1,600
| +0.1% | +$15.8K |
|
1224
Huntington Bancshares
HBAN
$35.9B
| $14M | ﹤0.01% |
1,335,415
-2,600
| -0.2% | -$25.9K |
|
1225
Expedia Group
EXPE
$39.4B
| $13.9M | ﹤0.01% |
163,247
+10
| +0% | +$848 |
|
Similar funds
T. Rowe Price Associates's Q4 2014 Portfolio in Review
As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
- T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
- T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
- T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.
Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.